loading
  • Trang chủ
  • Sách, tuyển tập
  • Possible new role for angiotensin-converting enzyme inhibitors in treating glomerulonephritis / Soliman, A.R.;El Meligi, A.A.;El Semari, M.;El Shemi, M.;Mahmoud, H.
Sách, tuyển tập Tài liệu điện tử

Possible new role for angiotensin-converting enzyme inhibitors in treating glomerulonephritis / Soliman, A.R.;El Meligi, A.A.;El Semari, M.;El Shemi, M.;Mahmoud, H.

Tác giả : Soliman, A.R.;El Meligi, A.A.;El Semari, M.;El Shemi, M.;Mahmoud, H.

Năm xuất bản : 2003

Chủ đề : 1. Angiotensin-Converting Enzyme Inhibitors. 2. Blood Urea Nitrogen. 3. Case-Control Studies. 4. Chronic Disease. 5. Creatinine. 6. Glomerulonephritis. 7. Hypertension. 8. Immunoassay. 9. Proteinuria.

Chia sẻ

Thông tin chi tiết

Tóm tắt :

399-406 Serum transforming growth factor-beta [TGF-beta1] production was estimated for 10 patients with essential hypertension, 12 patients with glomerulonephritis [5 hypertensive and 7 normotensive] and 10 healthy controls. The glomerulonephritis group received angiotensin-converting enzyme inhibitor captopril 25-75 mg/day for 4 weeks. Blood urea, serum creatinine, 24-hour urinary protein and serum TGF-beta1 were then re-estimated. Urea and creatinine were significantly higher in the hypertension and glomerulonephritis groups than in the controls and also higher in the glomerulonephritis group than the hypertension group. TGF-beta1 was significantly higher in the glomerulonephritis groups than in the control and hypertension groups. TGF-beta1 and 24-hour urinary protein were significantly reduced in the glomerulonephritis group
Chia sẻ


Hiển thị MARC

 Thông tin dữ liệu nguồn

 Thư viện  Ký hiệu xếp giá  Dữ liệu nguồn
Tổ chức y tế thế giới
https://iris.who.int/handle/10665/119290